Is Eli Lilly (LLY) Below Fair Value After Its FDA Win?

Eli Lilly stock has delivered very strong gains over the past five years, yet current valuation checks still point to a meaningful gap between the share price and an intrinsic value estimate. At the same time, shorter term swings, including a recent weekly pullback, keep raising the question of how much of the company’s drug pipeline and pipeline-related news is already reflected in the US$1,160 price.

• Eli Lilly has returned about 376.4% over five years, which puts a lot of focus on whether the current price still leaves room based on fundamentals.
• New approvals and late stage data around obesity and diabetes treatments such as Mounjaro, Zepbound and retatrutide can support cash flow expectations. However, execution and safety risks around this concentrated drug portfolio may limit how much value investors are comfortable assigning today.
• The Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiple checks both point to the stock screening as undervalued, with a value score of 4 that suggests a mixed picture rather than a straightforward bargain or an obviously expensive stock.

The issue now is whether Eli Lilly’s current valuation, including an intrinsic value estimate that sits about 31.3% above the market price, still offers a margin that looks attractive after such a strong five year run.

Spot opportunities that share Eli Lilly’s mix of strong returns and an undervalued screen by reviewing hand picked 50 high quality undervalued stocks in similar quality territory.

Is Eli Lilly a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Eli Lilly might be worth today. On this view, Eli Lilly generated roughly US$13.6b of free cash flow over the last twelve months, and the model assumes that cash flows keep growing rather than tapering off quickly, which is consistent with a company still investing behind a broad drug portfolio.

Those cash flows translate into an estimated intrinsic value of about $1,688 per share, compared with a current share price near $1,160. That gap implies the stock screens as roughly 31.3% undervalued on this DCF output. The recent FDA approval for Mounjaro in reducing cardiovascular risk in adults with type 2 diabetes helps explain why the model incorporates robust cash generation while the share price has not fully closed the gap.

On this discounted cash flow view, Eli Lilly stock currently appears undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 31.3%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eli Lilly.

Is Eli Lilly a Bargain on Earnings?

The P/E ratio is a useful way to sanity check what you are paying for each dollar of Eli Lilly earnings. On this measure, Eli Lilly trades at about 38.7x earnings, which is well above the broader pharmaceuticals industry average of 16.4x, but below a peer group average near 50.0x.

A tailored fair P/E ratio of about 45.5x reflects what might be reasonable for Eli Lilly given its size, profitability profile and risk mix. Against that yardstick, the current 38.7x multiple sits at a discount, suggesting the stock does not fully reflect the earnings power that would be implied by this fair multiple, even after a strong multi year share price run.

On the market multiple check, Eli Lilly stock appears undervalued relative to the earnings multiple the model views as fair.

See what the numbers say about this price — find out in our valuation breakdown.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Eli Lilly valuation checks leave off. They spell out what would need to be true about Eli Lilly's future growth, margins and earnings for the stock to be worth materially more or less than today's price, and they live on Simply Wall St's Community page. Each narrative links a fair value estimate to a clear story about catalysts and risks so you can track which version of events appears to be unfolding over time.

Community views on Eli Lilly sit far apart, with one side seeing room in the current price and the other flagging a stretched set of expectations.

Bull case: roughly fairly valued

"The main growth driver, tirzepatide, is well protected for years to come, according to drug-patent data, the earliest generic entry for Mounjaro is estimated ~2036..."

Read the full Bull Case to see why Eli Lilly could be undervalued

Bear case: 18% overvalued

"The likelihood of significant drug pricing reforms in the U.S., combined with initiatives to increase pricing parity between the U.S. and Europe, threatens to sharply limit Eli Lilly's future pricing power and compress both future revenue growth and net margins..."

Read the full Bear Case to see why Eli Lilly could be overvalued

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

Eli Lilly screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple cross check, even after a sharp move in the share price. The agreement between these methods suggests the current price still bakes in some caution about execution and concentration risk in its obesity and diabetes portfolio. For you, the key question is whether Eli Lilly can sustain the cash generation and earnings power implied by those models without major safety or pricing setbacks. That single assumption is likely to decide whether today’s apparent discount is an opportunity or a warning.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com